Bellevue Group’s Astrana Health ASTH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-163,155
Closed -$5.06M 155
2025
Q1
$5.06M Sell
163,155
-42,084
-21% -$1.4M 0.11% 88
2024
Q4
$6.47M Sell
205,239
-48,943
-19% -$2.32M 0.12% 89
2024
Q3
$14.7M Buy
254,182
+3,565
+1% +$175K 0.24% 81
2024
Q2
$10.2M Buy
250,617
+240,361
+2,344% +$9.53M 0.17% 88
2024
Q1
$431K Buy
+10,256
New +$400K 0.01% 136

Other funds holding ASTH

Bellevue Group's ASTH Position: Q2 2025 in Review

Bellevue Group sold out of Astrana Health (ASTH) in Q2 2025, closing a stake of 163,155 shares — an estimated $5.06M sold.

Bellevue Group first reported a position in ASTH in Q1 2024 and held it in 5 quarters. The position peaked at $14.7M in Q3 2024. 162 funds tracked by Wall St. Rank hold ASTH as of Q2 2025.

  • Bellevue Group reported no remaining Astrana Health position as of Q2 2025 after selling out during the quarter.
  • Bellevue Group sold 163,155 Astrana Health shares in Q2 2025, an estimated $5.06M.
  • Bellevue Group first reported a position in Astrana Health in Q1 2024 and held it in 5 quarters.
  • Bellevue Group's Astrana Health position peaked at $14.7M in Q3 2024.
  • 162 funds tracked by Wall St. Rank held Astrana Health as of Q2 2025.

Based on Bellevue Group's 13F filing for Q2 2025, filed 14 Aug 2025.